Clinical Trials Logo

Clinical Trial Summary

The finding of gastric dysplasia not associated with macroscopic lesions (DNAML) or the follow-up of dysplasia after endoscopic resection (DAER) is a challenging dilemma. In the last few years, radiofrequency ablation (RFA) has become a recognized tool in the treatment of dysplastic Barrett's esophagus, but its use in gastric dysplasia has not yet been studied. The investigators aim to study the efficacy, safety and tolerability of RFA in the treatment of dysplastic gastric mucosa.


Clinical Trial Description

Gastric cancer is the fourth most common cancer and the second leading cause of cancer related death worldwide. The 10-year survival of patients with this malignancy is 20% due to advanced disease at the time of diagnosis. Screening programs in countries with a high incidence of gastric neoplasia aim to detect early stage cancer, suitable for curative treatment. Well-differentiated dysplastic gastric lesions limited to the mucosa (when non-ulcerated or ulcerated and less than 3 cm) or limited to the superficial submucosa (when less than 3 cm and with no lymphatic or vascular invasion) have a negligible risk of lymph node metastasis and are suitable for endoscopic curative treatment.

Endoscopic mucosal resection (EMR) and endoscopic submucosal dissection (ESD) have been increasingly used in this setting with promising results. However, even with these advanced techniques, en bloc and R0 resection is not possible in up to 13-15% and 16-26% of the cases, respectively. The presence of dysplasia after endoscopic resection (DAER) in the post-resection scar presents a challenging dilemma due to the technical difficulty, and associated complications, of performing subsequent EMR/ESD in fibrotic tissue. Another issue of concern is the presence of gastric dysplasia not associated with macroscopic lesions (DNAML). In such cases, a targeted endoscopic treatment is difficult and clinical management is not standardized.

Radiofrequency ablation (RFA) has been increasingly advocated for the treatment of dysplastic Barrett's esophagus (BE) and early esophageal squamous cell carcinoma (ESCC), but its use in gastric dysplasia has not yet been tested. The investigators aim to study the role of gastric RFA in the treatment of DNAML and DAER. ;


Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT01523912
Study type Interventional
Source Hospital Sao Joao
Contact
Status Completed
Phase Phase 4
Start date January 2011
Completion date May 2015

See also
  Status Clinical Trial Phase
Completed NCT00339989 - Cervical Cancer Early Endpoints and Determinants
Completed NCT01954836 - Short-Term Fasting During Chemotherapy in Patients With Gynecological Cancer- a Randomized Controlled Cross-over Trial N/A
Not yet recruiting NCT03979014 - Nonavalent Prophylactic HPV Vaccine (GARDASIL9) After Local Conservative The NOVEL Trial Phase 3
Completed NCT02065297 - Quantitative and Functional Study of TH17 Lymphocytes in Horton's Disease (HD)
Recruiting NCT02049658 - The Sensitivity and Specificity of Sniff Dog as a Tool in Diagnosing the Suspected Tumor Patients
Recruiting NCT02049645 - The Suitability of Sniff Dog as a Tool in Screening Tumors
Completed NCT03415126 - A Study of ASN007 in Patients With Advanced Solid Tumors Phase 1
Enrolling by invitation NCT00792649 - Comparison Between HD+ Endoscopy and Standard Videoendoscopy in Screening Colonoscopy N/A
Recruiting NCT05158712 - Genetic Factors and Pheochromocytomas in Neoplasia Type 2
Completed NCT01962103 - Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors Phase 1/Phase 2
Terminated NCT01456143 - Optical Imaging of Head and Neck Cancer N/A
Recruiting NCT04341181 - ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic Profiling Phase 2
Recruiting NCT02925234 - The Drug Rediscovery Protocol (DRUP Trial) Phase 2